Government prohibits distribution, sale of Buclizine as ‘appetite stimulant’

New Delhi: The Union Health Ministry has prohibited the distribution and sale of anti-histamine drug Buclizine as an appetite stimulant “in public interest” under the Drugs and Cosmetics Act. The drug will, however, be allowed to be marketed for “symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness.”

According to a notification from the ministry, the Central government regulates the manufacture, sale or distribution of Buclizine and its formulations for use in human beings, subject to conditions that the manufacturer “shall label the container of Buclizine and its formulation and also mention in conspicuous manner on the package insert and promotional literature of Buclizine and its formulation with the words ‘Not to be used as appetite stimulant'”.

It was brought to the notice of the government that the use of the drug Buclizine as appetite stimulant for human use was not rational, the notification stated.

The matter was examined by a subject expert committee constituted by the government.

The committee stated that no clinical trial study report on human beings to justify the use of Buclizine as an appetite stimulant has been produced by the manufacturers and hence, the committee had not recommended the continued marketing of the drug as an appetite stimulant.

The Drugs Technical Advisory Board had also recommended prohibiting the manufacture, sale and distribution of Buclizine for the indication “as appetite stimulant” in public interest and continuing the marketing for the indications “symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness”.

“After examination of the recommendations of the Subject Expert Committee and Drugs Technical Advisory Board, the Central Government is satisfied that the use of said drug Buclizine do not have any therapeutic value claimed for as an appetite stimulant and is likely to involve risk to human beings,” the notification said.

  • Related Posts

    Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

    US President Donald Trump on Monday said nine pharmaceutical manufacturers, including Sun Pharma, have reached agreements with his administration to lower prescription drug prices for Americans in line with the…

    FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

    Mumbai: The Maharashtra Nodal Cyber Police have registered an FIR against 22 foreign medical graduates for allegedly uploading fake and suspicious documents on Maharashtra Medical Council (MMC) portal to obtain…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

    Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

    FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

    FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

    FUJIFILM India is zeroing in on Indian Gut with Advanced Therapeutic Endoscopy

    FUJIFILM India is zeroing in on Indian Gut with Advanced Therapeutic Endoscopy

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government